

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6491393

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MATTHEW GARDENER	01/21/2019
JAYNE HAMMERSLEY	01/21/2019
MARIA GROVES	01/16/2019
GARETH REES	01/16/2019
SADHANA PODICHETTY	01/22/2019
ANDREW BILLINTON	01/21/2019
RECEIVING PARTY DATA	
Name:	MEDIMMUNE LIMITED
Street Address:	MILSTEIN BUILDING, GRANTA PARK
City:	CAMBRIDGE
State/Country:	GREAT BRITAIN
Postal Code:	CB21 6GH
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17020247
CORRESPONDENCE DATA	
Fax Number:	(617)979-9301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617)979-9300
Email:	anastasia.danilova@whitecase.com
Correspondent Name:	WHITE & CASE LLP
Address Line 1:	75 STATE STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	1848081-0002-103-302
NAME OF SUBMITTER:	ANASTASIA DANILOVA
SIGNATURE:	/Anastasia Danilova/
DATE SIGNED:	01/12/2021
Total Attachments: 12	

source=1848081-0002-103-302 Assignment#page1.tif
source=1848081-0002-103-302 Assignment#page2.tif
source=1848081-0002-103-302 Assignment#page3.tif
source=1848081-0002-103-302 Assignment#page4.tif
source=1848081-0002-103-302 Assignment#page5.tif
source=1848081-0002-103-302 Assignment#page6.tif
source=1848081-0002-103-302 Assignment#page7.tif
source=1848081-0002-103-302 Assignment#page8.tif
source=1848081-0002-103-302 Assignment#page9.tif
source=1848081-0002-103-302 Assignment#page10.tif
source=1848081-0002-103-302 Assignment#page11.tif
source=1848081-0002-103-302 Assignment#page12.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Matt GARDENER, Jayne HAMMERSLEY, Maria GROVES, Gareth REES, Sadhana PODICHETTY** and **Andrew BILLINTON**, hereby sell and assign to **MEDIMMUNE LIMITED**, a corporation formed under the laws of United Kingdom, whose mailing address is Milstein Building, Granta Park, Cambridge, United Kingdom CB21 6GH (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTI-PrP ANTIBODIES AND USES THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of October 15, 2018 (also known as United States Application No. 16/093,687, which is the U.S. national phase of International Application No. PCT/EP2017/058010, International Filing Date April 4, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

/Jeremiah
B. Frueauf,
#66,638/

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 21st Jan 2019 Signature of Inventor: [Signature]
Matt GARDENER

MATTHEW

M.T.
MATTHEW
GARDENER

Date: _____ Signature of Inventor: _____
Jayne HAMMERSLEY

21-1-19

Date: _____ Signature of Inventor: _____
Maria GROVES

Date: _____ Signature of Inventor: _____
Gareth REES

Date: _____ Signature of Inventor: _____
Sadhana PODICHETTY

Date: _____ Signature of Inventor: _____
Andrew BILLINTON

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Matt GARDENER, Jayne HAMMERSLEY, Maria GROVES, Gareth REES, Sadhana PODICHETTY** and **Andrew BILLINTON**, hereby sell and assign to **MEDIMMUNE LIMITED**, a corporation formed under the laws of United Kingdom, whose mailing address is Milstein Building, Granta Park, Cambridge, United Kingdom CB21 6GH (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTI-PrP ANTIBODIES AND USES THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of October 15, 2018 (also known as United States Application No. 16/093,687, which is the U.S. national phase of International Application No. PCT/EP2017/058010, International Filing Date April 4, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

/Jeremiah
B. Frueauf,
#66,638/

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.


The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Matt GARDENER

Date: 21st January 2019 Signature of Inventor: 
Jayne HAMMERSLEY

Date: _____ Signature of Inventor: _____
Maria GROVES

Date: _____ Signature of Inventor: _____
Gareth REES

Date: _____ Signature of Inventor: _____
Sadhana PODICHETTY

Date: _____ Signature of Inventor: _____
Andrew BILLINTON

10368325_1.docx

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Matt GARDENER, Jayne HAMMERSLEY, Maria GROVES, Gareth REES, Sadhana PODICHETTY** and **Andrew BILLINTON**, hereby sell and assign to **MEDIMMUNE LIMITED**, a corporation formed under the laws of United Kingdom, whose mailing address is Milstein Building, Granta Park, Cambridge, United Kingdom CB21 6GH (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTI-PrP ANTIBODIES AND USES THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of October 15, 2018 (also known as United States Application No. 16/093,687, which is the U.S. national phase of International Application No. PCT/EP2017/058010, International Filing Date April 4, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

/Jeremiah
B. Frueauf,
#66,638/

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Matt GARDENER

Date: _____ Signature of Inventor: _____
Jayne HAMMERSLEY

Date: 16th Jan 2019 Signature of Inventor: 
Maria GROVES

Date: _____ Signature of Inventor: _____
Gareth REES

Date: _____ Signature of Inventor: _____
Sadhana PODICHETTY

Date: _____ Signature of Inventor: _____
Andrew BILLINTON

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Matt GARDENER, Jayne HAMMERSLEY, Maria GROVES, Gareth REES, Sadhana PODICHETTY** and **Andrew BILLINTON**, hereby sell and assign to **MEDIMMUNE LIMITED**, a corporation formed under the laws of United Kingdom, whose mailing address is Milstein Building, Granta Park, Cambridge, United Kingdom CB21 6GH (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTI-PrP ANTIBODIES AND USES THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of October 15, 2018 (also known as United States Application No. 16/093,687, which is the U.S. national phase of International Application No. PCT/EP2017/058010, International Filing Date April 4, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

/Jeremiah
B. Frueauf,
#66,638/

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Matt GARDENER

Date: _____ Signature of Inventor: _____
Jayne HAMMERSLEY

Date: _____ Signature of Inventor: _____
Maria GROVES

Date: 16th JANUARY 2019 Signature of Inventor: D. REES
Gareth REES

Date: _____ Signature of Inventor: _____
Sadhana PODICHETTY

Date: _____ Signature of Inventor: _____
Andrew BILLINTON

10368325_1.docx

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Matt GARDENER, Jayne HAMMERSLEY, Maria GROVES, Gareth REES, Sadhana PODICHETTY** and **Andrew BILLINTON**, hereby sell and assign to **MEDIMMUNE LIMITED**, a corporation formed under the laws of United Kingdom, whose mailing address is Milstein Building, Granta Park, Cambridge, United Kingdom CB21 6GH (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTI-PrP ANTIBODIES AND USES THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of October 15, 2018 (also known as United States Application No. 16/093,687, which is the U.S. national phase of International Application No. PCT/EP2017/058010, International Filing Date April 4, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

/Jeremiah
B. Frueauf,
#66,638/

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Matt GARDENER

Date: _____ Signature of Inventor: _____
Jayne HAMMERSLEY

Date: _____ Signature of Inventor: _____
Maria GROVES

Date: _____ Signature of Inventor: _____
Gareth REES

Date: 22 Jan 2019 Signature of Inventor: S Podichetty
Sadhana PODICHETTY

Date: _____ Signature of Inventor: _____
Andrew BILLINTON

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Matt GARDENER, Jayne HAMMERSLEY, Maria GROVES, Gareth REES, Sadhana PODICHETTY** and **Andrew BILLINTON**, hereby sell and assign to **MEDIMMUNE LIMITED**, a corporation formed under the laws of United Kingdom, whose mailing address is Milstein Building, Granta Park, Cambridge, United Kingdom CB21 6GH (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **ANTI-PrP ANTIBODIES AND USES THEREOF** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of October 15, 2018 (also known as United States Application No. 16/093,687, which is the U.S. national phase of International Application No. PCT/EP2017/058010, International Filing Date April 4, 2017), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

/Jeremiah
B. Frueauf,
#66,638/

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Matt GARDENER

Date: _____ Signature of Inventor: _____
Jayne HAMMERSLEY

Date: _____ Signature of Inventor: _____
Maria GROVES

Date: _____ Signature of Inventor: _____
Gareth REES

Date: _____ Signature of Inventor: _____
Sadhana PODICHETTY

Date: 21st JAN 2019 Signature of Inventor: _____
Andrew BILLINTON

10368325_1.docx